Ocugen’s Cash Runway Stretches to 2028 as Gene Therapy Pipeline Nears Key Milestones
08.05.2026 - 19:52:09 | boerse-global.de
Ocugen has bought itself a multi-year breathing space. A $115 million convertible note offering, completed on May 7, has pushed the biotech’s cash runway into 2028, giving management the financial firepower to steer three gene therapy candidates toward regulatory decisions.
The net proceeds from the deal came in at roughly $100 million. Ocugen wasted no time in deploying a chunk of that to clean up its balance sheet, fully repaying a double-digit million-dollar loan from Avenue Capital. After that paydown, the company’s cash position stands at approximately $99 million.
The new notes carry a 6.75% coupon and mature in 2034, a marked improvement on the 12.5% interest rate attached to the retired Avenue Capital debt. To cap dilution for existing shareholders, Ocugen capped the conversion mechanism. The initial conversion price is set at $2.68 per share, a healthy premium to the current stock price.
Clinical Data Points Converge
The refinancing comes as Ocugen’s pipeline generates tangible results. The phase 2 study of OCU410, a gene therapy for geographic atrophy of the eye, showed a 31% reduction in lesion growth at the mid-dose after 12 months — a statistically significant result that management notes is roughly double the efficacy of approved competitors.
Should investors sell immediately? Or is it worth buying Ocugen?
That candidate is now being prepared for its final clinical phase. Meanwhile, the company has already wrapped up patient enrollment for the pivotal study of its Stargardt disease therapy. An interim analysis is due in the third quarter of this year, with top-line data expected by mid-2027.
The lead candidate, OCU400 for retinitis pigmentosa, has also completed enrollment for its phase 3 trial. Ocugen plans to initiate a rolling submission for regulatory approval in the third quarter.
Rising Costs, Steady Stock
The intensified research effort is driving up expenses. Operating costs hit roughly $19 million in the first quarter, while the net loss per share widened slightly to $0.06.
Despite the widening loss, the stock has been a standout performer. At €1.27 on Friday, the shares have more than doubled over the past 12 months, though volatility remains elevated.
Analysts see further upside. Oppenheimer has reiterated its buy rating with a $10.00 price target, while Canaccord Genuity is even more bullish at $12.00.
Ocugen at a turning point? This analysis reveals what investors need to know now.
Global Partner Hunt Begins
With the financing secured, management is turning its attention to commercialization. The company is actively seeking global partners to secure worldwide market access and boost enterprise value.
The next major catalyst arrives in the third quarter, when interim Stargardt data is released. Positive results would bring a regulatory filing within reach next year, and with cash now locked in through 2028, Ocugen has the luxury of time to see its pipeline through.
Ad
Ocugen Stock: New Analysis - 8 May
Fresh Ocugen information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Ocugen’s Aktien ein!
FĂĽr. Immer. Kostenlos.
